AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company founded in 1999, partnering with SandboxAQ (Alphabet spinoff) in June 2023 to use quantum-inspired AI drug discovery and development tools reducing time and cost of bringing life-saving treatments to clinic. AstraZeneca uses SandboxAQ’s AQ-FEP software combining quantum mechanical equations accuracy with AI speed and power on classical computing hardware for treatments for cancer, Alzheimer’s, Parkinson’s, and other conditions. In June 2025, AstraZeneca joined collaborative research program with IonQ, AWS, and NVIDIA developing quantum-accelerated computational chemistry workflow delivering 20x speedup in time-to-solution compared to prior benchmarks. AstraZeneca applies quantum computing to molecular simulations, drug-target binding calculations, and pharmaceutical R&D optimization. AstraZeneca serves global pharmaceutical market requiring quantum-enhanced drug discovery, computational chemistry, and AI-accelerated pharmaceutical development for breakthrough treatments.
Explore other quantum computing companies in similar categories or regions.
Information for Educational Purposes Only: All information about AstraZeneca is provided for informational and educational purposes only. This is not investment, financial, or professional advice.
No Warranties: While we strive for accuracy, Quantum Zeitgeist makes no warranties regarding the accuracy, completeness, or timeliness of company information. The quantum technology industry evolves rapidly, and information may become outdated.
No Endorsement: Inclusion in Quantum Navigator does not constitute an endorsement, recommendation, or verification of AstraZeneca's claims, technology, or business viability.
Do Your Own Research: Always conduct independent due diligence and consult qualified professionals (financial advisors, lawyers, etc.) before making investment, business, or career decisions.
For more information, see our Terms of Service and Privacy Policy.